

MILC-APIC TOOL ^{v1.4}

Mother · Infant · Lactation — Assess · Plan · Implement · Check

Structured consultation form

Pharmaceutical care during lactation

Mark the appropriate option(s); fill the remaining fields with data.

Date of consultation

Provider / institution

Patient identifier

Consultant details

Do not enter personal data — use an ID or chart number.

Name, surname and licence (PWZ) number.

1

Clinical interview

MILC: Mother-Infant-Lactation

MILC

REASON FOR CONSULTATION & PATIENT NEEDS

Describe the needs and the reason for consultation.

DRUG-RELATED PROBLEM (DRP) SCREENING

Problem status:

☐ No problem ☐ Potential problem ☐ Actual problem

Specific problem (mark all that apply):

☐ No effect of drug treatment despite correct use ☐ Effect of drug treatment not optimal

☐ No therapy despite indication ☐ (Possible) adverse drug event occurring

☐ Unnecessary drug treatment ☐ Unclear problem / complaint

Describe the cause (if applicable)

MOTHER

Weight

Height

BMI

in kg

in cm

calculated automatically

Chronic conditions

Concomitant medications

Allergies

LACTATION

Estimated share of mother's milk in the child's diet (mark one):

☐ 100 % ☐ 75 % ☐ 50 % ☐ 25 % and less

Breastfeeding problems before?

☐ No ☐ Yes

Baby additionally receives (mark all that apply):

☐ Formula ☐ Animal milk ☐ Expressed mother's milk ☐ Human donor milk ☐ Parenteral nutrition
☐ Solid foods

Comments regarding lactation

INFANT

Age

Weight

Chronic conditions & current health status

Medications, supplements

Allergies

MEDICATION(S) OF CONCERN

Medication name	Dose	Dosing regimen	Form	How long taken

Complete one Assess block per medication of concern (up to three). If a block is not needed, mark it "Not applicable" and leave it blank.

ASSESS · DRUG 1

primary medication

Medication assessed

Summary of Product Characteristics — SmPC (point 4.6)

Summarise the SmPC statement on use during lactation.

General risk of drug use during lactation (mark one):

☐ No data ☐ Very low risk ☐ Low risk ☐ Moderate risk ☐ High risk ☐ Very high risk

Assessment based on (mark all that apply):

☐ No data ☐ LactMed ☐ InfantRisk App ☐ Hale's Manual ☐ Expert opinion ☐ SmPC
☐ e-lactancia ☐ Clinical guidelines ☐ Other: _____

HOW MUCH OF THE DRUG PASSES INTO BREASTMILK?

M/P ratio

Oral bioavailability

Pediatric dose

Other data

Relative infant dose — RID (mark one):

☐ No data ☐ < 1 % ☐ 1–5 % ☐ 6–10 % ☐ 11–25 % ☐ > 25 %

Can the amount of drug in breastmilk be clinically significant? (mark one):

☐ No data ☐ Yes ☐ No ☐ Not possible to assess

Reported adverse events on breastmilk / lactation (mark all that apply):

☐ No data ☐ None reported ☐ Decreased milk supply ☐ Increased milk supply
☐ Change in milk colour ☐ Change in milk taste ☐ Change in milk odour ☐ Change in milk flow
☐ Other: _____

Reported adverse events in the breastfed child due to exposure (mark all that apply):

☐ No data ☐ Reported mild / self-limiting / few ☐ Reported serious / requiring medical intervention
☐ Reported isolated (specific to the individual situation)

Describe what was reported

Additional drug information

ASSESS · DRUG 2

additional medication

☐ Not applicable — no further drug to assess (leave this block blank)

Medication assessed

Summary of Product Characteristics — SmPC (point 4.6)

Summarise the SmPC statement on use during lactation.

General risk of drug use during lactation (mark one):

☐ No data ☐ Very low risk ☐ Low risk ☐ Moderate risk ☐ High risk ☐ Very high risk

Assessment based on (mark all that apply):

☐ No data ☐ LactMed ☐ InfantRisk App ☐ Hale's Manual ☐ Expert opinion ☐ SmPC
☐ e-lactancia ☐ Clinical guidelines ☐ Other: _____

HOW MUCH OF THE DRUG PASSES INTO BREASTMILK?

M/P ratio

Oral bioavailability

Pediatric dose

Other data

Relative infant dose — RID (mark one):

☐ No data ☐ < 1 % ☐ 1–5 % ☐ 6–10 % ☐ 11–25 % ☐ > 25 %

Can the amount of drug in breastmilk be clinically significant? (mark one):

☐ No data ☐ Yes ☐ No ☐ Not possible to assess

Reported adverse events on breastmilk / lactation (mark all that apply):

☐ No data ☐ None reported ☐ Decreased milk supply ☐ Increased milk supply
☐ Change in milk colour ☐ Change in milk taste ☐ Change in milk odour ☐ Change in milk flow
☐ Other: _____

Reported adverse events in the breastfed child due to exposure (mark all that apply):

☐ No data ☐ Reported mild / self-limiting / few ☐ Reported serious / requiring medical intervention
☐ Reported isolated (specific to the individual situation)

Describe what was reported

Additional drug information

ASSESS · DRUG 3

additional medication

☐ Not applicable — no further drug to assess (leave this block blank)

Medication assessed

Summary of Product Characteristics — SmPC (point 4.6)

Summarise the SmPC statement on use during lactation.

General risk of drug use during lactation (mark one):

☐ No data ☐ Very low risk ☐ Low risk ☐ Moderate risk ☐ High risk ☐ Very high risk

Assessment based on (mark all that apply):

☐ No data ☐ LactMed ☐ InfantRisk App ☐ Hale's Manual ☐ Expert opinion ☐ SmPC
☐ e-lactancia ☐ Clinical guidelines ☐ Other: _____

HOW MUCH OF THE DRUG PASSES INTO BREASTMILK?

M/P ratio

Oral bioavailability

Pediatric dose

Other data

Relative infant dose — RID (mark one):

☐ No data ☐ < 1 % ☐ 1–5 % ☐ 6–10 % ☐ 11–25 % ☐ > 25 %

Can the amount of drug in breastmilk be clinically significant? (mark one):

☐ No data ☐ Yes ☐ No ☐ Not possible to assess

Reported adverse events on breastmilk / lactation (mark all that apply):

☐ No data ☐ None reported ☐ Decreased milk supply ☐ Increased milk supply
☐ Change in milk colour ☐ Change in milk taste ☐ Change in milk odour ☐ Change in milk flow
☐ Other: _____

Reported adverse events in the breastfed child due to exposure (mark all that apply):

☐ No data ☐ Reported mild / self-limiting / few ☐ Reported serious / requiring medical intervention
☐ Reported isolated (specific to the individual situation)

Describe what was reported

Additional drug information

3

Plan & Implement

PI

Planned interventions and how to implement them

Describe the tailored intervention plan and the steps for implementation. Also enter here information for other specialists.

Qualification for other services:

- ☐ None ☐ New medication ☐ Specialist consultation ☐ Medicines review
- ☐ Other: _____

4

Follow-up

C

Check outcomes & adherence

Follow-up date

Follow-up points to consider

Services provided

Based on (references / sources used)

Signature

Morze K, Szalek E, Waszyk-Nowaczyk M.
Poznan University of Medical Sciences